Cerity Partners’s Nurix Therapeutics NRIX Stock Holding History

Cerity Partners’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$207K	Buy	+13,328	New	+$221K	﹤0.01%	2866
2025 Q1	–	Sell	-10,743	Closed	-$241K	–	2572
2024 Q4	$241K	Buy	10,743 +1	+0%	+$23	﹤0.01%	2143
2024 Q3	$241K	Buy	+10,742	New	+$243K	﹤0.01%	2208
2024 Q2	–	Sell	-10,738	Closed	-$158K	–	2345
2024 Q1	$158K	Buy	+10,738	New	+$115K	﹤0.01%	2153

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Cerity Partners's NRIX Position: Q1 2026 in Review

Cerity Partners opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 13,328 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #2866 among its holdings. This is a return to the name: Cerity Partners previously reported a position in NRIX as recently as Q4 2024.

Cerity Partners first reported a position in NRIX in Q1 2024 and has held it in 4 quarters since. The position peaked at $241K in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Cerity Partners held 13,328 shares of Nurix Therapeutics worth $207K as of Q1 2026.
Nurix Therapeutics was a new Cerity Partners position in Q1 2026.
Nurix Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2866 holding.
Cerity Partners first reported a position in Nurix Therapeutics in Q1 2024 and has held it in 4 quarters since.
Cerity Partners's Nurix Therapeutics position peaked at $241K in Q3 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.